Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL-6301
- Development stage
- Preclinical
- Lead developer
- Zai Lab
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ZL-6301 is a next-generation antibody-drug conjugate (ADC) targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1). It is being developed for the treatment of solid tumors. The drug leverages an ADC modality to deliver cytotoxic agents specifically to ROR1-expressing cancer cells, aiming to improve antitumor efficacy while minimizing off-target toxicity. The originator of ZL-6301 is MabCare Therapeutics, and it is being developed by Zai Lab. As of late 2024, the highest development phase reached by ZL-6301 is preclinical, with plans announced to initiate a global Phase 1 study in solid tumors in 2025[1][2][5][7][8].
- Other names
- ZL 6301ZL6301ZL-6301
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on ZL-6301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL-6301.